STOCK TITAN
  1. Home
  2. Sec-filings
  3. ESLA
  4. [EFFECT] Estrella Immunopharma, Inc. SEC Filing

[EFFECT] Estrella Immunopharma, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 23, 2026 4:00 P.M.
Form: S-1
CIK: 0001844417
Company Name: Estrella Immunopharma, Inc.
File Number: 333-292331

Source: View Original Filing on SEC EDGAR

Estrella Immunopharma

NASDAQ:ESLA

View ESLA Stock Overview →

ESLA Rankings

#5573 Ranked by Market Cap
N/A Ranked by Dividends

ESLA Latest News

Feb 9, 2026
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Feb 3, 2026
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Jan 6, 2026
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
Jan 5, 2026
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Dec 4, 2025
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

ESLA Latest SEC Filings

Feb 13, 2026
[424B3] Estrella Immunopharma, Inc. Prospectus Filed Pursuant to Rule 424(b)(3)
Jan 21, 2026
[S-1/A] Estrella Immunopharma, Inc. Amends IPO Registration Statement
Jan 16, 2026
[S-1/A] Estrella Immunopharma, Inc. Amends IPO Registration Statement
Jan 6, 2026
[8-K] Estrella Immunopharma, Inc. Reports Material Event
Jan 13, 2026
[8-K] Estrella Immunopharma, Inc. Reports Material Event

ESLA Stock Data

52.54M
15.95M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
EMERYVILLE